• End-to-end strategy development and execution for the Knee portfolio in APAC with a focus on priority markets ANZ, China, India, and Japan. • Assessed, revamped, and implemented the go to market model in India in 2021 resulting in improved SGP and successful robotics launch in 2022. • Navigated impact of volume-based procurement in China in 2022 while improving overall financial metrics for APAC.• Developed the 10-year portfolio strategy encompassing financial, supply chain, share gain and education metrics. • Executed Knee Division portfolio strategy, led the rationalisation of legacy brands and sub brands across APAC. Implemented brand ladder, floor pricing and return on price erosion metrics resulting in financial successes outlined above.• Improved performance of in-country marketers through coaching and mentoring sessions. Coached teams during the launch of two new flagship primary knee line extensions in 2022, with first OUS cases undertaken in APAC ahead of schedule.• Led cross functional (RA, Marketing, R&D, Market Access, Education) launch excellence teams with representation from market, region, and global functions to reduce time to market for key product launches.

• Promoted to lead knee marketing team/function to improve primary knee revenue and improve operational efficiency.• Returned the primary knee platform to growth for first time since 2017. • Executed brand campaign to improve perception of the flagship primary knee brand in Australia. Reversed trend of declining market share to deliver an increase in share of 1%. • Delivered sales mastery program in conjunction with local, regional, and global education partners resulting in high volume surgeon conversions delivering additional $3M+ AUD annual revenue. • Exceeded revenue targets for 7 out of 8 quarters in 2019 & 2020 mitigating COVID impact. • Improved capability within the knee marketing team to deliver focused digital media campaigns. Role subsequently spanned all business units. • Led launch excellence team delivering the fastest & largest adoption of cementless knee technology In Australia from <6% in 2020 to >30% in 2021.• Devised and led lifecycle management process to rationalise legacy brands from the market. Collaborated with supply chain to remove $7M+ AUD and 12% overall inventory reduction.• Led workstream for commercial excellence program to develop rapid deal desk and calculator, pricing corridors, and enabling technology rebates to drive commercial solutions for providers and payors.

• Launched flagship revision knee system into the Australian market, delivering >$5M AUD revenue growth and >10% market share gain in 2019.• Drove focus on sales planning and execution resulting in a 600% increase in recorded sales calls monthly. Monitored content of sales calls for trends, provided feedback on content and suggestions for future planning. • Organised effective and well attended professional education activities including a regional symposium with 170 HCP attendees and state-based cadaver labs with over 30 competitor? HCPs in attendance. 97% of surgeon attendees surveyed indicated they would change their clinical practice as a result.• Improved user experience of loan kit booking system across joint reconstruction to reduce errors, improve communication and reduce time taken to log booking.

• Led coordination of clinical support to orthopaedic surgeons and theatre staff for joint reconstruction portfolio (hips, knees, shoulders) across New Zealand with a focus on the lower North and upper South Island territories. • Identified areas of need for upskilling. Mapped and implemented an education plan to enable support of computer aided surgery, alternative alignment in knees and shoulder/reverse shoulder arthroplasty. • Implemented a centralised case coverage booking system, giving the entire NZ team visibility of upcoming surgeries for greater efficiency.

Partnering with DePuy Synthes and their joints product portfolio, this role involved selling primary and revision hip and knee products. Delivered first class customer support to orthopaedic surgeons and theatre staff.

This role involved providing clinical and sales support for St. Jude Medical pacemakers, cardiac resynchronisation therapy devices (bivents) and implantable cardioverter-defibrillators.

Development and characterisation of novel lipid formulations to improve the bioavailability of poorly water soluble drugs using in vitro and in vivo techniques.

Employed in the Quality Assurance department at Pfizer Ireland Pharmaceuticals.